<DOC>
	<DOCNO>NCT00002704</DOCNO>
	<brief_summary>Phase II trial study effectiveness radiation therapy follow chemotherapy treat child CNS relapse acute lymphoblastic leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy radiation therapy may kill cancer cell .</brief_summary>
	<brief_title>Radiation Therapy Chemotherapy Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy toxicity intensify systemic treatment delayed central nervous system ( CNS ) irradiation child acute lymphoblastic leukemia isolate CNS disease . II . Determine efficacy systemic thiotepa reduce clear blast cerebrospinal fluid patient . III . Evaluate toxicity single dose thiotepa follow dexamethasone , vincristine , daunorubicin , triple intrathecal therapy patient . IV . Determine response rate intrathecal sustain release cytarabine ( DTC101 ) patient first bone marrow remission first isolate CNS relapse . V. Assess safety toxicity DTC101 patient . OUTLINE : Patients significant neurologic symptom ( e.g. , seizure , cranial nerve palsy , paresis , mental status change ) enter directly Induction regimen receive Therapeutic Window . The following acronym use : ARA-C Cytarabine , NSC-63878 ASP Asparaginase , NSC-109229 ( E. coli ) 106977 ( Erwinia ) CF Leucovorin calcium , NSC-3590 CTX Cyclophosphamide , NSC-26271 DM Dexamethasone , NSC-34521 DNR Daunorubicin , NSC-82151 DTC101 Sustained release cytarabine G-CSF Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 HC Hydrocortisone , NSC-10483 Mesna Mercaptoethane sulfonate , NSC-113891 MP Mercaptopurine , NSC-755 MTX Methotrexate , NSC-740 TIT Triple Intrathecal Therapy , IT MTX/IT HC/IT ARA-C TMP-SMX Trimethoprim-sulfamethoxazole TSPA Thiotepa , NSC-6396 VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 THERAPEUTIC WINDOW : Single Agent Chemotherapy . TSPA DTC101 . ** Thiotepa window close 7/6/98 ** ** DTC101 window open 11/15/99 ** INDUCTION : 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy . DM/DNR/VCR ; plus TIT . CONSOLIDATION : 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy . ARA-C/ASP ; plus TIT . INTENSIFICATION I : 4-Drug Combination Chemotherapy Leucovorin Rescue plus Triple Intrathecal Therapy . CTX/MP/MTX/VP-16 ; CF ; plus TIT . RE-INDUCTION : 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy . DM/DNR/VCR ; plus TIT . INTENSIFICATION II : 6-Drug Combination Chemotherapy Leucovorin Rescue plus Triple Intrathecal Therapy . ARA-C/ASP/CTX/MP/MTX/VP-16 ; CF ; plus TIT . CHEMORADIOTHERAPY : Radiotherapy plus 3-Drug Combination Chemotherapy . Craniospinal irradiation use x-rays energy 4-6 MV ( electron acceptable spinal cord irradiation ) ; plus ASP/DM/VCR . MAINTENANCE : 2-Drug Combination Chemotherapy Alternating 2-Drug Combination Chemotherapy . MP/MTX ; alternate CTX/VCR .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute lymphoblastic leukemia first bone marrow remission ( M1 ) first isolated initial CNS relapse More 5 WBC/microliter cerebrospinal fluid ( CSF ) blast cytospin OR immunophenotypic proof ( encourage ) relapse CSF Identifiable blast presence 2 CSF sample 3 week apart If Bcell terminal deoxynucleotidyl transferase ( TdT ) OR CD10 If Tcell TdT alone OR CD7 PATIENT CHARACTERISTICS : Age : Over 6 month 21 year relapse Patients receive sustained release cytarabine Performance status : Older 10 year Karnofsky great 50 % Less 10 year Lansky great 50 % Platelet count great 40,000/mm3 Bilirubin less 2.0 mg/dL SGPT le 5 time normal Creatinine le 1.5 time normal age Normal metabolic parameter ( serum electrolytes , calcium , phosphorus ) No clinical evidence obstructive hydrocephalus , compartmentalization CSF flow , ventriculoperitoneal ventriculoatrial shunt PRIOR CONCURRENT THERAPY : Prior cumulative anthracycline dose le 375 mg/sqm Patients receive sustained release cytarabine At least 7 day since prior investigational drug At least 3 week since prior CNS direct therapy ( 6 week prior nitrosourea ) At least 1 week since intrathecal chemotherapy At least 8 week since prior craniospinal radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>TdT positive childhood acute lymphoblastic leukemia</keyword>
</DOC>